The company did an investor call last year which is worth a...

The company did an investor call last year which is worth a listen.

The focus on the product has never been on a single vertical and certainly not solely aimed at grain silos.

Virbac's trials weren't done in official manner and the possibility of re-infestation could arise due to cows coming into contact with themselves and wondering around pastures.

They were going after a niche in animal health, they were looking for a significant improvement from their current pesticide range they use. Limited R&D budget meant they were happy to pass.

Bio-Gene's biggest value proposition is in the crop protection and public health verticals targeting mosquito control imo. Those are the biggest markets and we have already seen compelling results out in the field and human testing for both.